Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HFA-152A propellant · 1 trial · 1 indication
FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and measured using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.
| Arm | Type | Description |
|---|---|---|
| HFA-152A propellant followed by HFA-134A propellant | EXPERIMENTAL | - |
| HFA-134A propellant followed by HFA-152A propellant | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HFA-152A propellant | DRUG | HFA-152A propellant is administered via oral inhalation |
| HFA-134A propellant | DRUG | HFA-134A propellant is administered via oral inhalation |
Inclusion Criteria: Participants are eligible to be included in the study if all the following criteria apply: * Male or female; females may be of childbearing potential, of nonchildbearing potential, or postmenopausal. * Participant must be 18 to 45 years of age inclusive, at the time of screenin...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
HFA-152a propellant is an investigational small molecule being studied for use in asthma. It is a propellant intended for pressurized inhalers, and a clinical trial has assessed its potential for airway sensitivity reactions in adults with mild asthma.
HFA-152a propellant does not target a specific molecular target. It is a propellant, a substance used to deliver medication from a pressurized inhaler. Its role is to serve as a carrier for asthma medications, rather than to interact with a biological target.
HFA-152a propellant is being developed by GSK plc, a biopharma company traded on the New York Stock Exchange under the ticker GSK. GSK is conducting clinical research on this propellant for use in pressurized inhalers for asthma.
HFA-152a propellant is in Phase 1 clinical development. It is an investigational product and has not been approved by regulatory authorities. A Phase 1 trial has been completed to assess its safety and tolerability in adults with mild asthma.
HFA-152a propellant has one completed clinical trial, NCT06702462, titled "A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma." This Phase 1 trial enrolled 20 participants in the United States.
No, HFA-152a propellant is not the same as HFA-134a. In clinical trial NCT06702462, HFA-152a is the test propellant and HFA-134a is the reference propellant. The study compares the two to assess the potential for airway sensitivity reactions in adults with mild asthma.